| Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. | |
| | |
MedLine Citation:
|
PMID: 16107485 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population. METHODS AND RESULTS: In 18 countries at 149 hospitals, 4,809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Ischaemic events were assessed at 30 days and 6 months and mortality was assessed at 1 year. We previously reported that abciximab was superior to tirofiban considering the composite rate of death or myocardial infarction at 30 days among all patients and at 6 months among those with an acute coronary syndrome (ACS). At 1-year follow-up death occurred in 46 (1.9%) patients who received tirofiban and 42 (1.7%) patients who received abciximab (hazard ratio 1.10, 95% CI 0.72-1.67; P=0.660). Mortality rates for patients with ACS were 2.3% with tirofiban vs. 2.2% with abciximab (hazard ratio 1.03, 95% CI 0.64-1.67; P=0.897) and those without ACS were 1.4 vs. 1.0% (hazard ratio 1.32, 95% CI 0.56-3.13; P=0.530). CONCLUSION: At 1 year, tirofiban provided a similar level of survival benefit compared with abciximab. |
| | |
Authors:
|
Debabrata Mukherjee; Eric J Topol; Michel E Bertrand; Steen D Kristensen; Howard C Herrmann; Franz-Josef Neumann; Steven J Yakubov; Jean-Pierre Bassand; Rick R McClure; Gregg W Stone; Diego Ardissino; David J Moliterno; |
Related Documents
:
|
18426435 - Clinical implications of qrs duration and qt peak prolongation in patients with suspect... 16344425 - Renal function and risk of myocardial infarction in an elderly population: the rotterda... 20506285 - Angiographic morphology impacts outcomes in stemi patients with lad occlusion. 9114755 - Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. 23661975 - Acute posterior circulation infarct due to bicuspid aortic valve vegetation: an uncommo... 11103025 - Early coronary angioplasty for acute myocardial infarction complicated by cardiogenic s... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2005-08-17 |
Journal Detail:
|
Title: European heart journal Volume: 26 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-11-15 Completed Date: 2006-05-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: England |
Other Details:
|
Languages: eng Pagination: 2524-8 Citation Subset: IM |
Affiliation:
|
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA. mukherjee@uky.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary
/
methods*,
mortality Antibodies, Monoclonal / therapeutic use* Drug Therapy, Combination Female Follow-Up Studies Humans Immunoglobulin Fab Fragments / therapeutic use* Male Middle Aged Myocardial Infarction / mortality, therapy* Myocardial Revascularization / methods*, mortality Platelet Aggregation Inhibitors / therapeutic use* Stents* Survival Analysis Treatment Outcome Tyrosine / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 143653-53-6/abciximab; 144494-65-5/tirofiban; 55520-40-6/Tyrosine |
| Comments/Corrections | |
Comment In:
|
Eur Heart J. 2006 Jan;27(1):119-20; author reply 120
[PMID:
16278228
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Auxin response factors ARF6 and ARF8 promote jasmonic acid production and flower maturation.
Next Document: Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with...